

Table 3*Hierarchy of Evidence (analytic themes, descriptive themes and subthemes)*

Treatment outcomes			Reported strengths and weaknesses of dual diagnosis treatment	
Psychiatric symptomatology	Substance use symptomatology	Treatment retention	Facilitators of change	Barriers to change
<i>PTSD</i> - Integrated treatment superiority (Coffey et al., 2016; Garland et al., 2016; McGovern et al., 2011; Mills et al., 2012; Sannibale et al., 2013) - Non-integrated treatment superiority (Foa et al., 2013) - No difference between treatment models (McGovern et al., 2015)	- Integrated treatment superiority (Courbasson et al., 2012; Garland et al., 2016; McGovern et al., 2015) - Non-integrated treatment superiority (Foa et al., 2013; Sannibale et al., 2013) - No difference between treatment models (Coffey et al., 2016; Gouzoulis-Mayfrank et al., 2015; Graham et al., 2016; McGovern et al., 2011; Mills et al., 2012; Wüsthoff et al., 2014)	Retention (Coffey et al., 2016; Courbasson et al., 2012; Gouzoulis-Mayfrank et al., 2015; Graham et al., 2016; McGovern et al., 2011) Engagement (Graham et al., 2016; McGovern et al., 2015) Contact (Courbasson et al., 2012) Completion (Coffey et al., 2016; McGovern et al., 2011) Dropout (Courbasson et al., 2012)	- Therapeutic characteristics (Coffey et al., 2016; Courbasson et al., 2012; Garland et al., 2016; Graham et al., 2016; Wüsthoff et al., 2014) - Setting characteristics (Coffey et al., 2016; Garland et al., 2016; Mills et al., 2012)	- Therapeutic characteristics (Coffey et al., 2016) - Setting characteristics (Coffey et al., 2016)
<i>Anxiety and depression</i> - Integrated treatment superiority (Coffey et al., 2016; Courbasson et al., 2012; Garland et al., 2016) - No difference between treatment models (Graham et al., 2016; Mills et al., 2012; Wüsthoff et al., 2014)				
<i>Psychosis</i> - No difference between treatment models (Gouzoulis-Mayfrank et al., 2015)				
<i>ED</i> - Integrated treatment superiority (Courbasson et al., 2012)				

11

11

6

6

1
